264 related articles for article (PubMed ID: 9850028)
1. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group.
J Clin Oncol; 1998 Dec; 16(12):3832-42. PubMed ID: 9850028
[TBL] [Abstract][Full Text] [Related]
2. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.
Palumbo A; Bringhen S; Caravita T; Merla E; Capparella V; Callea V; Cangialosi C; Grasso M; Rossini F; Galli M; Catalano L; Zamagni E; Petrucci MT; De Stefano V; Ceccarelli M; Ambrosini MT; Avonto I; Falco P; Ciccone G; Liberati AM; Musto P; Boccadoro M;
Lancet; 2006 Mar; 367(9513):825-31. PubMed ID: 16530576
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial.
Mateos MV; Richardson PG; Schlag R; Khuageva NK; Dimopoulos MA; Shpilberg O; Kropff M; Spicka I; Petrucci MT; Palumbo A; Samoilova OS; Dmoszynska A; Abdulkadyrov KM; Schots R; Jiang B; Esseltine DL; Liu K; Cakana A; van de Velde H; San Miguel JF
J Clin Oncol; 2010 May; 28(13):2259-66. PubMed ID: 20368561
[TBL] [Abstract][Full Text] [Related]
4. Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis.
Kapoor P; Rajkumar SV; Dispenzieri A; Gertz MA; Lacy MQ; Dingli D; Mikhael JR; Roy V; Kyle RA; Greipp PR; Kumar S; Mandrekar SJ
Leukemia; 2011 Apr; 25(4):689-96. PubMed ID: 21233832
[TBL] [Abstract][Full Text] [Related]
5. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma.
San Miguel JF; Schlag R; Khuageva NK; Dimopoulos MA; Shpilberg O; Kropff M; Spicka I; Petrucci MT; Palumbo A; Samoilova OS; Dmoszynska A; Abdulkadyrov KM; Delforge M; Jiang B; Mateos MV; Anderson KC; Esseltine DL; Liu K; Deraedt W; Cakana A; van de Velde H; Richardson PG
J Clin Oncol; 2013 Feb; 31(4):448-55. PubMed ID: 23233713
[TBL] [Abstract][Full Text] [Related]
6. Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study.
Cavo M; Benni M; Ronconi S; Fiacchini M; Gozzetti A; Zamagni E; Cellini C; Tosi P; Baccarani M; Tura S;
Haematologica; 2002 Sep; 87(9):934-42. PubMed ID: 12217805
[TBL] [Abstract][Full Text] [Related]
7. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.
Facon T; Mary JY; Hulin C; Benboubker L; Attal M; Pegourie B; Renaud M; Harousseau JL; Guillerm G; Chaleteix C; Dib M; Voillat L; Maisonneuve H; Troncy J; Dorvaux V; Monconduit M; Martin C; Casassus P; Jaubert J; Jardel H; Doyen C; Kolb B; Anglaret B; Grosbois B; Yakoub-Agha I; Mathiot C; Avet-Loiseau H;
Lancet; 2007 Oct; 370(9594):1209-18. PubMed ID: 17920916
[TBL] [Abstract][Full Text] [Related]
8. Interferon-alpha 2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. A randomized, controlled trial. The Nordic Myeloma Study Group.
Ann Intern Med; 1996 Jan; 124(2):212-22. PubMed ID: 8533996
[TBL] [Abstract][Full Text] [Related]
9. Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients.
Bladé J; San Miguel JF; Alcalá A; Maldonado J; Sanz MA; García-Conde J; Moro MJ; Alonso C; Besalduch J; Zubizarreta A
J Clin Oncol; 1993 Jun; 11(6):1165-71. PubMed ID: 8501503
[TBL] [Abstract][Full Text] [Related]
10. Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group.
Beksac M; Haznedar R; Firatli-Tuglular T; Ozdogu H; Aydogdu I; Konuk N; Sucak G; Kaygusuz I; Karakus S; Kaya E; Ali R; Gulbas Z; Ozet G; Goker H; Undar L
Eur J Haematol; 2011 Jan; 86(1):16-22. PubMed ID: 20942865
[TBL] [Abstract][Full Text] [Related]
11. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study.
Mateos MV; Hernández JM; Hernández MT; Gutiérrez NC; Palomera L; Fuertes M; Díaz-Mediavilla J; Lahuerta JJ; de la Rubia J; Terol MJ; Sureda A; Bargay J; Ribas P; de Arriba F; Alegre A; Oriol A; Carrera D; García-Laraña J; García-Sanz R; Bladé J; Prósper F; Mateo G; Esseltine DL; van de Velde H; San Miguel JF
Blood; 2006 Oct; 108(7):2165-72. PubMed ID: 16772605
[TBL] [Abstract][Full Text] [Related]
12. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
Oken MM; Harrington DP; Abramson N; Kyle RA; Knospe W; Glick JH
Cancer; 1997 Apr; 79(8):1561-7. PubMed ID: 9118039
[TBL] [Abstract][Full Text] [Related]
13. "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.
Gasparetto C; Gockerman JP; Diehl LF; de Castro CM; Moore JO; Long GD; Horwitz ME; Keogh G; Chute JP; Sullivan KM; Neuwirth R; Davis PH; Sutton LM; Anderson RD; Chao NJ; Rizzieri D
Biol Blood Marrow Transplant; 2010 Jan; 16(1):70-7. PubMed ID: 19733251
[TBL] [Abstract][Full Text] [Related]
14. Treatment of multiple myeloma.
San Miguel JF; Bladé Creixenti J; García-Sanz R
Haematologica; 1999 Jan; 84(1):36-58. PubMed ID: 10091392
[TBL] [Abstract][Full Text] [Related]
15. Increased conventional chemotherapy does not improve survival in multiple myeloma: long-term results of two PETHEMA trials including 914 patients.
Bladé J; San Miguel JF; Fontanillas M; Esteve J; Maldonado J; Alcalá A; Brunet S; García-Conde J; Besalduch J; Moro MJ; Fernández-Calvo J; Conde E; Font L; Gardella S; Carnero M; Carbonell F; Martí JM; Hernández-Martín J; Ortega F; Besses C; Ribera JM; Trujillo J; Escudero ML; Rozman C; Estapé J; Montserrat E
Hematol J; 2001; 2(4):272-8. PubMed ID: 11920260
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.
Mateos MV; Oriol A; Martínez-López J; Gutiérrez N; Teruel AI; de Paz R; García-Laraña J; Bengoechea E; Martín A; Mediavilla JD; Palomera L; de Arriba F; González Y; Hernández JM; Sureda A; Bello JL; Bargay J; Peñalver FJ; Ribera JM; Martín-Mateos ML; García-Sanz R; Cibeira MT; Ramos ML; Vidriales MB; Paiva B; Montalbán MA; Lahuerta JJ; Bladé J; Miguel JF
Lancet Oncol; 2010 Oct; 11(10):934-41. PubMed ID: 20739218
[TBL] [Abstract][Full Text] [Related]
17. Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma.
Hernández JM; García-Sanz R; Golvano E; Bladé J; Fernandez-Calvo J; Trujillo J; Soler JA; Gardella S; Carbonell F; Mateo G; San Miguel JF
Br J Haematol; 2004 Oct; 127(2):159-64. PubMed ID: 15461621
[TBL] [Abstract][Full Text] [Related]
18. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials.
Gregory WM; Richards MA; Malpas JS
J Clin Oncol; 1992 Feb; 10(2):334-42. PubMed ID: 1531068
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.
Hulin C; Facon T; Rodon P; Pegourie B; Benboubker L; Doyen C; Dib M; Guillerm G; Salles B; Eschard JP; Lenain P; Casassus P; Azaïs I; Decaux O; Garderet L; Mathiot C; Fontan J; Lafon I; Virion JM; Moreau P
J Clin Oncol; 2009 Aug; 27(22):3664-70. PubMed ID: 19451428
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study.
Morabito F; Bringhen S; Larocca A; Wijermans P; Victoria Mateos M; Gimsing P; Mazzone C; Gottardi D; Omedè P; Zweegman S; José Lahuerta J; Zambello R; Musto P; Magarotto V; Schaafsma M; Oriol A; Juliusson G; Cerrato C; Catalano L; Gentile M; Isabel Turel A; Marina Liberati A; Cavalli M; Rossi D; Passera R; Rosso S; Beksac M; Cavo M; Waage A; San Miguel J; Boccadoro M; Sonneveld P; Palumbo A; Offidani M
Am J Hematol; 2014 Apr; 89(4):355-62. PubMed ID: 24273190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
